A phase 3 clinical trial of ravulizumab (CHAMPION MG, NCT03920293) confirmed the efficacy and good safety profile of complement C5 inhibitors [36, 37], and a recently reported postmarketing surveillance study of eculizumab across three indications (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and AChR Ab+ gMG) in over 1000 patients in Japan over a period of more than 10 years has confirmed the safety profile of eculizumab in clinical practice to be consistent with that in clinical trials [38]. This evidence concerns the gene C5 and atypical hemolytic-uremic syndrome.